ArticleBio-protocol2026
A Rapid and High-Recovery Extracellular Vesicle (EVs) Isolation Technique from Blood Samples.
Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) circulating in blood serve as non-invasive "liquid biopsies," carrying molecular cargo that reflects the physiological and pathological state of distant cells. Their analysis is crucial for understanding disease mechanisms and discovering novel biomarkers. Clinically, blood EVs hold significant promise for early disease diagnosis, prognostic assessment, and monitoring treatment response in diverse areas such as organ transplantation, cancer, and neurological disorders. Current EV isolation techniques, beyond ultracentrifugation, include size exclusion chromatography (separation by size for high purity) and immunoaffinity capture (using antibodies for high specificity). Here, we present a simplified, rapid, and reproducible method for isolating EVs from small-volume blood samples. This protocol consistently yields a concentrated EV pellet covering 50-300 nm EVs, amenable to direct downstream analysis. Developed and validated in our laboratory using human, porcine, and murine blood samples, this method has proven instrumental in identifying EV-based biomarkers for predicting outcomes related to organ transplantation. The protocol's adaptability and reliance on readily prepared, cost-effective reagents further enhance its utility. This scalable approach can be further integrated with subsequent purification or enrichment steps to optimize sample preparation for protein and nucleic acid assays. Key features • This method uses Ficoll-isolated plasma or centrifuged serum from any source, fresh to frozen. • Protocol is easy to handle, fast, and has fewer technical details. • 50-200 μL of plasma can be used to isolate enough EVs to run 5-8 western blot gels. • Protocol acquires 50-300 nm EVs enriched with markers and nucleic acids. • EVs isolated by this method can be further purified.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.